Anti-GD2 antibodies in treatment of high-risk Neuroblastoma: present and perspectives

1 Dec

Written By Carla Aguilera

Original title: Neuroblastome de haut risque - Place actuelle et perspectives de l’utilisation des anticorps monoclonaux anti-GD2

Valteau-Couanet D, Minard-Colin V, Pasqualini C.

Med Sci (Paris). 2019 Dec;35(12):997-1000. French. doi:10.1051/medsci/2019197. Epub 2020 Jan 6. PMID: 31903906.

2019

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1).

Exosomal microRNAs from Longitudinal Liquid Biopsies for the Prediction of Response to Induction Chemotherapy in HR-NBL Patients